Variant report
Variant | esv3432462 |
---|---|
Chromosome Location | chr6:32280930-32287047 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs74209703 | chr6:32281016-32281017 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
2 | rs34838815 | chr6:32281042-32281043 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
3 | rs34729596 | chr6:32281044-32281045 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
4 | rs534724164 | chr6:32281086-32281087 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
5 | rs527541993 | chr6:32281087-32281088 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
6 | rs542503108 | chr6:32281143-32281144 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
7 | rs561125668 | chr6:32281147-32281148 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
8 | rs531726379 | chr6:32281150-32281151 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
9 | rs185535670 | chr6:32281165-32281166 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
10 | rs370135497 | chr6:32281179-32281180 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
11 | rs2021905 | chr6:32281201-32281202 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
12 | rs370855327 | chr6:32281229-32281230 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
13 | rs189437217 | chr6:32281259-32281260 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
14 | rs182087255 | chr6:32281308-32281309 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
15 | rs374278326 | chr6:32281341-32281342 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
16 | rs185233044 | chr6:32281342-32281343 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
17 | rs1018434 | chr6:32281360-32281361 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
18 | rs142121401 | chr6:32281389-32281390 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
19 | rs189988295 | chr6:32281409-32281410 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs28366179 | chr6:32281412-32281413 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
21 | rs139331886 | chr6:32281446-32281447 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs144094035 | chr6:32281465-32281466 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs371559634 | chr6:32281468-32281469 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs1018433 | chr6:32281510-32281511 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
25 | rs200326143 | chr6:32281513-32281514 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs572289321 | chr6:32281516-32281517 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs201620532 | chr6:32281534-32281535 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs542891581 | chr6:32281575-32281576 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs560952483 | chr6:32281587-32281588 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs3864303 | chr6:32281621-32281622 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
31 | rs371841497 | chr6:32281627-32281628 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs565046736 | chr6:32281673-32281674 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
33 | rs386699276 | chr6:32281674-32281675 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs1018431 | chr6:32281676-32281677 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
35 | rs1018430 | chr6:32281688-32281689 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
36 | rs572476332 | chr6:32281824-32281825 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs530364638 | chr6:32281836-32281837 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs9268212 | chr6:32281889-32281890 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
39 | rs371615633 | chr6:32281914-32281915 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs2069026 | chr6:32281958-32281959 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
41 | rs6903871 | chr6:32282019-32282020 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
42 | rs547261 | chr6:32282033-32282034 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
43 | rs11966368 | chr6:32282036-32282037 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
44 | rs181142031 | chr6:32282040-32282041 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs553520773 | chr6:32282053-32282054 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs2395141 | chr6:32282068-32282069 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
47 | rs9268213 | chr6:32282081-32282082 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
48 | rs554861323 | chr6:32282092-32282093 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs186461124 | chr6:32282110-32282111 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs114797575 | chr6:32282188-32282189 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Follicular lymphoma | 20505157 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Leukemia | 21518781 | CNVD |
Cancer | 21637783 | CNVD |
Facial dysmorphism | 22105932 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Diffuse large b-cell lymphoma | 18287131 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Acute myeloid leukemia | 16864856 | CNVD |
Breast cancer | 21264507 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Cancer | 16751803 | CNVD |
Bladder cancer | 19088036 | CNVD |
Wilms tumour | 21544195 | CNVD |
Uveal melanoma | 21693616 | CNVD |
Biliary cancer | 19435499 | CNVD |
Malaria | 21533027 | CNVD |
Retinoblastoma | 19183342 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Prostate cancer | 18632612 | CNVD |
Breast cancer | 21858162 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Lung cancer | 18438408 | CNVD |
Autism | 21448237 | CNVD |
Melanoma | 18172304 | CNVD |
Breast cancer | 20668451 | CNVD |
Cancer | 20668451 | CNVD |
Lung cancer | 20668451 | CNVD |
Ovarian cancer | 20668451 | CNVD |
Pancreas cancer | 20668451 | CNVD |
Prostate cancer | 20668451 | CNVD |
Ependymoma | 19289631 | CNVD |
Breast cancer | 22844521 | CNVD |
Gestational infection | 22844521 | CNVD |
HIV/AIDS | 22844521 | CNVD |
Head circumference | 22844521 | CNVD |
Infertility | 22844521 | CNVD |
Ovarian cancer | 22844521 | CNVD |
Prostate cancer | 22844521 | CNVD |
Psoriasis | 22844521 | CNVD |
Recurrent birth weight diabetes | 22844521 | CNVD |
Rheumatoid arthritis | 22844521 | CNVD |
Sclerosis systemic | 22844521 | CNVD |
Systemic lupus erythematosus | 22844521 | CNVD |
Obesity | 22844521 | CNVD |
Recurrent pregnancy loss | 22844521 | CNVD |
Intellectual disability | 21811512 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Congenital anomalies of the kidney and urinary tract | 18694510 | CNVD |
Nasopharyngeal cancer | 22815911 | CNVD |
Ovarian cancer | 21781307 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Basal cell lymphoma | 21115979 | CNVD |
Acute lymphoblastic leukemia | 21339820 | CNVD |
Autism | 22495311 | CNVD |
Cancer | 16790693 | CNVD |
Cervical cancer | 21062161 | CNVD |
Esophageal adenocarcinoma | 18820669 | CNVD |
Systemic lupus erythematosus | 17503323 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Urothelial carcinoma | 18382360 | CNVD |
Cancer | 21183584 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Renal cell carcinoma | 18765545 | CNVD |
Oral squamous cell carcinoma | 17134496 | CNVD |
Gastric cancer | 17908304 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Splenic marginal zone lymphoma | 21957467 | CNVD |
Schizophrenia | 19571808 | CNVD |
Malignant peripheral nerve sheath tumor | 18522746 | CNVD |
Neuroblastoma | 16790693 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
abnormal development | 18461090 | CNVD |
Melanoma | 17363583 | CNVD |
Breast cancer | 16397240 | CNVD |
Retinoblastoma | 22278416 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Systemic lupus erythematosus | 20877625 | CNVD |
Cleidocranial dysplasia | 18696259 | CNVD |
Holoprosencephaly | 21359414 | CNVD |
Liposarcoma | 21253554 | CNVD |
Uveal melanoma | 20484589 | CNVD |
Fibroblasts | 20926602 | CNVD |
Systemic lupus erythematosus | 19279649 | CNVD |
Retinoblastoma | 16790693 | CNVD |
Acute myocardial infarction | 18032375 | CNVD |
Renal cell carcinoma | 19150565 | CNVD |
Systemic lupus erythematosus | 19591781 | CNVD |
Attention deficit hyperactivity disorder | 19287146 | CNVD |
Autism | 19287146 | CNVD |
Erythema nodosum in leprosy | 19287146 | CNVD |
Henoch-schoenlein purpura | 19287146 | CNVD |
Liver cirrhosis | 19287146 | CNVD |
Systemic lupus erythematosus | 19287146 | CNVD |
Autoimmune disease | 19135723 | CNVD |
Congenital adrenal hyperplasia | 18478071 | CNVD |
Systemic lupus erythematosus | 19287147 | CNVD |
Osteosarcoma | 16790693 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Biliary cancer | 20360734 | CNVD |
Breast cancer | 20360734 | CNVD |
Coronary artery disease | 20360734 | CNVD |
Crohn''s disease | 20360734 | CNVD |
Hypertension | 20360734 | CNVD |
Rheumatoid arthritis | 20360734 | CNVD |
Type 1 diabetes | 20360734 | CNVD |
Type 2 diabetes | 20360734 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
Cancer | 22183965 | CNVD |
Melanoma | 22183965 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Incontinentia Pigmenti | 22033527 | CNVD |
Cutaneous T-cell lymphoma | 21881587 | CNVD |
Primary central nervous system lymphoma | 21088137 | CNVD |
Encephalopathy | 20692195 | CNVD |
Non-syndromic sensorineural hearing loss | 17122850 | CNVD |
Immune disease | 17576883 | CNVD |
Multiple myeloma | 16616336 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
Breast cancer | 22522925 | CNVD |
Non-syndromic sensorineural hearing loss | 21293372 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr6:32275800-32281400 | Weak transcription | Breast Myoepithelial Primary Cells | Breast |
2 | chr6:32281400-32282800 | Enhancers | Breast Myoepithelial Primary Cells | Breast |
3 | chr6:32281600-32282200 | Enhancers | Foreskin Keratinocyte Primary Cells skin03 | Skin |
4 | chr6:32282800-32288000 | Weak transcription | Breast Myoepithelial Primary Cells | Breast |
5 | chr6:32284000-32285200 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
6 | chr6:32284000-32286200 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
7 | chr6:32284600-32284800 | Weak transcription | iPS-15b Cell Line | embryonic stem cell |
8 | chr6:32284800-32285000 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
9 | chr6:32285000-32286200 | Weak transcription | iPS-15b Cell Line | embryonic stem cell |
10 | chr6:32285200-32286000 | Flanking Active TSS | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
11 | chr6:32285400-32285800 | Enhancers | K562 | blood |
12 | chr6:32285600-32286000 | Enhancers | Primary hematopoietic stem cells | blood |
13 | chr6:32286000-32286200 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
14 | chr6:32286000-32286600 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
15 | chr6:32286000-32286600 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
16 | chr6:32286200-32286800 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
17 | chr6:32286200-32294200 | Weak transcription | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
18 | chr6:32286400-32286800 | Enhancers | HUES48 Cell Line | embryonic stem cell |